Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

733 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating 'not applicable' responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study.
Merz EL, Kwakkenbos L, Carrier ME, Gholizadeh S, Mills SD, Fox RS, Jewett LR, Williamson H, Harcourt D, Assassi S, Furst DE, Gottesman K, Mayes MD, Moss TP, Thombs BD, Malcarne VL; SPIN Investigators. Merz EL, et al. Among authors: furst de. BMJ Open. 2018 Mar 6;8(3):e018641. doi: 10.1136/bmjopen-2017-018641. BMJ Open. 2018. PMID: 29511009 Free PMC article.
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W, Moreland LW, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR. Clements PJ, et al. Among authors: furst de. Arthritis Rheum. 1999 Jun;42(6):1194-203. doi: 10.1002/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7. Arthritis Rheum. 1999. PMID: 10366112 Free article. Clinical Trial.
Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis.
Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin R, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold J. Clements PJ, et al. Among authors: furst de. Arthritis Rheum. 1999 Nov;42(11):2372-80. doi: 10.1002/1529-0131(199911)42:11<2372::AID-ANR16>3.0.CO;2-J. Arthritis Rheum. 1999. PMID: 10555033 Free article.
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.
Clements PJ, Seibold JR, Furst DE, Mayes M, White B, Wigley F, Weisman MD, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Wong WK. Clements PJ, et al. Among authors: furst de. Semin Arthritis Rheum. 2004 Feb;33(4):249-63. doi: 10.1053/s0049-0172(03)00135-5. Semin Arthritis Rheum. 2004. PMID: 14978663 Clinical Trial.
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP; Scleroderma Lung Study Group. Khanna D, et al. Among authors: furst de. Arthritis Rheum. 2005 Feb;52(2):592-600. doi: 10.1002/art.20787. Arthritis Rheum. 2005. PMID: 15692967 Free article. Clinical Trial.
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, Mayes MD, Collier DH, Medsger TA Jr, Seibold JR; Relaxin Study Group; Scleroderma Clinical Trials Consortium. Khanna D, et al. Among authors: furst de. J Rheumatol. 2005 May;32(5):832-40. J Rheumatol. 2005. PMID: 15868618 Clinical Trial.
Outcome measurements in scleroderma: results from a delphi exercise.
Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, Kahaleh B, Wollheim FA, Baron M, Csuka ME, Emery P, Belch JF, Hayat S, Lally EV, Korn JH, Czirjak L, Herrick A, Voskuyl AE, Bruehlmann P, Inanc M, Furst DE, Black C, Ellman MH, Moreland LW, Rothfield NF, Hsu V, Mayes M, McKown KM, Krieg T, Siebold JR. Gazi H, et al. Among authors: furst de. J Rheumatol. 2007 Mar;34(3):501-9. Epub 2007 Feb 1. J Rheumatol. 2007. PMID: 17299843
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.
Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connelly K, Metersky M, Furst DE; Scleroderma Lung Study Group. Clements PJ, et al. Among authors: furst de. Ann Rheum Dis. 2007 Dec;66(12):1641-7. doi: 10.1136/ard.2007.069518. Epub 2007 May 7. Ann Rheum Dis. 2007. PMID: 17485423 Free PMC article.
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G; Scleroderma Lung Study Research Group. Tashkin DP, et al. Among authors: furst de. Am J Respir Crit Care Med. 2007 Nov 15;176(10):1026-34. doi: 10.1164/rccm.200702-326OC. Epub 2007 Aug 23. Am J Respir Crit Care Med. 2007. PMID: 17717203 Free PMC article. Clinical Trial.
733 results